Why Vertex Stock Got Mashed on Monday
The stock of niche financial software company (NASDAQ: VERX) didn't get a very good start to the trading week at all. Its value fell by nearly 10% that day, due largely to a quarterly earnings report that many considered to be underwhelming. By contrast, the benchmark S 500 index rose on the day, closing slightly (0.2%) higher.
That morning, Vertex revealed that its total revenue was slightly over $192 million in the third quarter, a figure that was up by nearly 13% year-over-year. Subscriptions, which form the bulk of its top line, grew by the same rate to almost $165 million.
Image source: Getty Images.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
384,50 €
-0,18 %
Klare Kaufstimmung: Vertex Pharmaceuticals Inc. hat 43 Buy-Einschätzungen und keine Sell-Einschätzung.
Die Community erwartet für Vertex Pharmaceuticals Inc. ein Kursziel von 464 €, was eine Steigerung von über 20% gegenüber 384.5 € bedeuten würde.
